featured
Tivantinib for Second-Line Treatment of MET-High, Advanced Hepatocellular Carcinoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Tivantinib for Second-Line Treatment of MET-High, Advanced Hepatocellular Carcinoma (METIV-HCC): A Final Analysis of a Phase 3, Randomised, Placebo-Controlled Study
Lancet Oncol 2018 Apr 03;[EPub Ahead of Print], L Rimassa, E Assenat, M Peck-Radosavljevic, M Pracht, V Zagonel, P Mathurin, E Rota Caremoli, C Porta, B Daniele, L Bolondi, V Mazzaferro, W Harris, N Damjanov, D Pastorelli, M Reig, J Knox, F Negri, J Trojan, C López López, N Personeni, T Decaens, M Dupuy, W Sieghart, G Abbadessa, B Schwartz, M Lamar, T Goldberg, D Shuster, A Santoro, J BruixFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.